Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Lesley Scott and Wendy Stevens.
Lesley Scott
Connection Strength
15,824
Wendy Stevens
  1. Integrating Molecular Diagnostics and GIS Mapping: A Multidisciplinary Approach to Understanding Tuberculosis Disease Dynamics in South Africa Using Xpert MTB/RIF. Diagnostics (Basel). 2023 Oct 10; 13(20).
    View in: PubMed
    Score: 0,893
  2. How South Africa Used National Cycle Threshold (Ct) Values to Continuously Monitor SARS-CoV-2 Laboratory Test Quality. Diagnostics (Basel). 2023 Aug 01; 13(15).
    View in: PubMed
    Score: 0,881
  3. Challenges and complexities in evaluating severe acute respiratory syndrome coronavirus 2 molecular diagnostics during the COVID-19 pandemic. Afr J Lab Med. 2022; 11(1):1429.
    View in: PubMed
    Score: 0,807
  4. Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting. J Mol Diagn. 2020 10; 22(10):1225-1237.
    View in: PubMed
    Score: 0,716
  5. Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care. J Acquir Immune Defic Syndr. 2017 09 01; 76(1):65-73.
    View in: PubMed
    Score: 0,585
  6. Performance of the Abbott RealTime MTB and MTB RIF/INH Assays in a Setting of High Tuberculosis and HIV Coinfection in South Africa. J Clin Microbiol. 2017 08; 55(8):2491-2501.
    View in: PubMed
    Score: 0,575
  7. Choosing a new CD4 technology: Can statistical method comparison tools influence the decision? Cytometry B Clin Cytom. 2017 11; 92(6):465-475.
    View in: PubMed
    Score: 0,574
  8. A meta-analysis of the performance of the Pima™ CD4 for point of care testing. BMC Med. 2015 Jul 25; 13:168.
    View in: PubMed
    Score: 0,505
  9. Laboratory evaluation of the Liat HIV Quant (IQuum) whole-blood and plasma HIV-1 viral load assays for point-of-care testing in South Africa. J Clin Microbiol. 2015 May; 53(5):1616-21.
    View in: PubMed
    Score: 0,492
  10. Multicenter feasibility study to assess external quality assessment panels for Xpert MTB/RIF assay in South Africa. J Clin Microbiol. 2014 Jul; 52(7):2493-9.
    View in: PubMed
    Score: 0,464
  11. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. J Clin Microbiol. 2014 Jun; 52(6):1818-23.
    View in: PubMed
    Score: 0,460
  12. Use of a prequalification panel for rapid scale-up of high-throughput HIV viral load testing. J Clin Microbiol. 2012 Dec; 50(12):4083-6.
    View in: PubMed
    Score: 0,415
  13. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011 Jul; 8(7):e1001061.
    View in: PubMed
    Score: 0,383
  14. Abbott RealTime HIV-1 m2000rt viral load testing: manual extraction versus the automated m2000sp extraction. J Virol Methods. 2011 Mar; 172(1-2):78-80.
    View in: PubMed
    Score: 0,368
  15. Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol. 2009 Oct; 47(10):3400-2.
    View in: PubMed
    Score: 0,334
  16. Ultra-high-throughput, automated nucleic acid detection of human immunodeficiency virus (HIV) for infant infection diagnosis using the Gen-Probe Aptima HIV-1 screening assay. J Clin Microbiol. 2009 Aug; 47(8):2465-9.
    View in: PubMed
    Score: 0,330
  17. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol. 2009 Jul; 47(7):2209-17.
    View in: PubMed
    Score: 0,328
  18. Diagnostic accuracy of self-collected tongue swabs for Mycobacterium tuberculosis complex detection in individuals being assessed for tuberculosis in South Africa using the Xpert MTB/RIF Ultra assay. Clin Microbiol Infect. 2025 Jan 28.
    View in: PubMed
    Score: 0,244
  19. A Comprehensive Clinical Assessment of the LumiraDx International Normalized Ratio (INR) Assay for Point-of-Care Monitoring in Anticoagulation Therapy. Diagnostics (Basel). 2024 Nov 28; 14(23).
    View in: PubMed
    Score: 0,241
  20. Tuberculosis testing patterns in South Africa to identify groups that would benefit from increased investigation. Sci Rep. 2023 11 27; 13(1):20875.
    View in: PubMed
    Score: 0,225
  21. Storage of Mycobacterium tuberculosis culture isolates in MicrobankTM beads at a South African laboratory. Afr J Lab Med. 2023; 12(1):2172.
    View in: PubMed
    Score: 0,224
  22. Painless Capillary Blood Collection: A Rapid Evaluation of the Onflow Device. Diagnostics (Basel). 2023 May 16; 13(10).
    View in: PubMed
    Score: 0,217
  23. Performance Evaluation of Four Qualitative RT-PCR Assays for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Microbiol Spectr. 2023 Feb 28; e0371622.
    View in: PubMed
    Score: 0,214
  24. Cross-municipality migration and spread of tuberculosis in South Africa. Sci Rep. 2023 02 15; 13(1):2674.
    View in: PubMed
    Score: 0,213
  25. Rapid Evaluation of the Xpert? Xpress CoV-2 plus and Xpert? Xpress CoV-2/Flu/RSV plus Tests. Diagnostics (Basel). 2022 Dec 22; 13(1).
    View in: PubMed
    Score: 0,211
  26. Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization-Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis?and Resistance to Rifampicin and Isoniazid. J Mol Diagn. 2023 01; 25(1):46-56.
    View in: PubMed
    Score: 0,208
  27. Implementation of an mHealth App to Promote Engagement During HIV Care and Viral Load Suppression in Johannesburg, South Africa (iThemba Life): Pilot Technical Feasibility and Acceptability Study. JMIR Form Res. 2022 Feb 02; 6(2):e26033.
    View in: PubMed
    Score: 0,199
  28. Antigen-Based Point of Care Testing (POCT) for Diagnosing SARS-CoV-2: Assessing Performance. Methods Mol Biol. 2022; 2452:45-62.
    View in: PubMed
    Score: 0,197
  29. Guidance for SARS-CoV-2 RNA-Based Molecular Assay Analytical Performance Evaluations. Methods Mol Biol. 2022; 2511:99-115.
    View in: PubMed
    Score: 0,197
  30. The Development of a Standardized Quality Assessment Material to Support Xpert® HIV-1 Viral Load Testing for ART Monitoring in South Africa. Diagnostics (Basel). 2021 Jan 22; 11(2).
    View in: PubMed
    Score: 0,185
  31. The Performance of the Abbott Real Time MTB RIF/INH Compared to the MTBDRplus V2 for the Identification of MDR-TB Among Isolates. Infect Drug Resist. 2020; 13:3301-3308.
    View in: PubMed
    Score: 0,181
  32. The role of serological testing in the SARS-CoV-2 outbreak. S Afr Med J. 2020 07 17; 110(9):842-845.
    View in: PubMed
    Score: 0,178
  33. Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Reader™ for rapid HIV testing in South Africa. BMC Infect Dis. 2020 May 04; 20(1):320.
    View in: PubMed
    Score: 0,176
  34. Cost and Impact of Dried Blood Spot Versus Plasma Separation Card for Scale-up of Viral Load Testing in Resource-limited Settings. Clin Infect Dis. 2020 03 03; 70(6):1014-1020.
    View in: PubMed
    Score: 0,174
  35. Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).
    View in: PubMed
    Score: 0,159
  36. Molecular characterisation of rifampicin-resistant Mycobacterium tuberculosis strains from Malawi. Afr J Lab Med. 2017; 6(2):463.
    View in: PubMed
    Score: 0,142
  37. Performance of Xpert® MTB/RIF among tuberculosis outpatients in Lilongwe, Malawi. Afr J Lab Med. 2017; 6(2):464.
    View in: PubMed
    Score: 0,142
  38. Diagnosis of opportunistic infections: HIV co-infections - tuberculosis. Curr Opin HIV AIDS. 2017 03; 12(2):129-138.
    View in: PubMed
    Score: 0,141
  39. Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control. Microbiol Spectr. 2017 01; 5(1).
    View in: PubMed
    Score: 0,140
  40. Options to Expand HIV Viral Load Testing in South Africa: Evaluation of the GeneXpert® HIV-1 Viral Load Assay. PLoS One. 2016; 11(12):e0168244.
    View in: PubMed
    Score: 0,139
  41. Human Immunodeficiency Virus (HIV)-Infected Patients Accept Finger Stick Blood Collection for Point-Of-Care CD4 Testing. PLoS One. 2016; 11(8):e0161891.
    View in: PubMed
    Score: 0,136
  42. Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):e34-43.
    View in: PubMed
    Score: 0,131
  43. Diagnosing childhood pulmonary tuberculosis using a single sputum specimen on Xpert MTB/RIF at point of care. S Afr Med J. 2015 Nov 10; 105(12):1044-8.
    View in: PubMed
    Score: 0,129
  44. A High Burden Human Immunodeficiency Virus and Tuberculosis Resource Limited Setting, Gains from Including Xpert MTB/RIF in the Diagnostic Algorithm of Fluid Specimens Submitted for Exclusion of Lymphoma by Immunophenotypic Analysis. PLoS One. 2015; 10(8):e0134404.
    View in: PubMed
    Score: 0,127
  45. Feasibility of performing multiple point of care testing for HIV anti-retroviral treatment initiation and monitoring from multiple or single fingersticks. PLoS One. 2013; 8(12):e85265.
    View in: PubMed
    Score: 0,113
  46. Prevalence, risk factors and risk perception of tuberculosis infection among medical students and healthcare workers in Johannesburg, South Africa. S Afr Med J. 2013 Sep 30; 103(11):853-7.
    View in: PubMed
    Score: 0,111
  47. Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010 Oct; 10(7):937-46.
    View in: PubMed
    Score: 0,090
  48. Should South Africa be performing nucleic acid testing on HIV enzyme-linked immunosorbent assay-negative samples? J Clin Microbiol. 2010 Sep; 48(9):3407-9.
    View in: PubMed
    Score: 0,089
  49. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis. 2010 Apr 15; 201 Suppl 1:S16-26.
    View in: PubMed
    Score: 0,088
  50. Evaluating new CD4 enumeration technologies for resource-constrained countries. Nat Rev Microbiol. 2008 Nov; 6(11 Suppl):S29-38.
    View in: PubMed
    Score: 0,079
  51. Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S40-51.
    View in: PubMed
    Score: 0,075
  52. CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S131-40.
    View in: PubMed
    Score: 0,075
  53. Fluorogenic LUX primer for quantitation of HIV-1 by real-time RT-PCR. Mol Biotechnol. 2006 Feb; 32(2):101-10.
    View in: PubMed
    Score: 0,065
  54. HIV/AIDS prevalence testing--merits, methodology and outcomes of a survey conducted at a large mining organisation in South Africa. S Afr Med J. 2006 Feb; 96(2):134-9.
    View in: PubMed
    Score: 0,065
  55. Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance. J Mol Diagn. 2024 Aug; 26(8):708-718.
    View in: PubMed
    Score: 0,058
  56. Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality. PLOS Glob Public Health. 2023; 3(9):e0001989.
    View in: PubMed
    Score: 0,055
  57. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022 09; 28(9):1785-1790.
    View in: PubMed
    Score: 0,051
  58. Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients. PLoS One. 2022; 17(2):e0262442.
    View in: PubMed
    Score: 0,050
  59. Monitored Implementation of COVID-19 Rapid Antigen Screening at Taxi Ranks in Johannesburg, South Africa. Diagnostics (Basel). 2022 Feb 03; 12(2).
    View in: PubMed
    Score: 0,050
  60. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022 03; 603(7902):679-686.
    View in: PubMed
    Score: 0,049
  61. Evaluation Protocol for SARS-CoV-2 Serological Assays. Methods Mol Biol. 2022; 2511:307-319.
    View in: PubMed
    Score: 0,049
  62. Validation of Roche immunoassay for severe acute respiratory coronavirus 2 in South Africa. S Afr J Infect Dis. 2021; 36(1):286.
    View in: PubMed
    Score: 0,048
  63. Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response. J Immunol Methods. 2021 09; 496:113096.
    View in: PubMed
    Score: 0,048
  64. Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa. PLoS One. 2021; 16(6):e0252317.
    View in: PubMed
    Score: 0,048
  65. Self-Sampling for SARS-CoV-2 Diagnostic Testing by Using Nasal and Saliva Specimens: Protocol for Usability and Clinical Evaluation. JMIR Res Protoc. 2021 May 28; 10(5):e24811.
    View in: PubMed
    Score: 0,047
  66. SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients. Front Plant Sci. 2021; 12:589940.
    View in: PubMed
    Score: 0,047
  67. Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid. J Clin Microbiol. 2021 02 18; 59(3).
    View in: PubMed
    Score: 0,046
  68. Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact. J Antimicrob Chemother. 2020 05 01; 75(5):1123-1129.
    View in: PubMed
    Score: 0,044
  69. Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. J Infect Dis. 2019 10 08; 220(220 Suppl 3):S99-S107.
    View in: PubMed
    Score: 0,042
  70. The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. J Antimicrob Chemother. 2018 10 01; 73(10):2667-2674.
    View in: PubMed
    Score: 0,039
  71. Molecular Detection of Mycobacterium tuberculosis from Stools in Young Children by Use of a Novel Centrifugation-Free Processing Method. J Clin Microbiol. 2018 09; 56(9).
    View in: PubMed
    Score: 0,039
  72. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018 01; 18(1):76-84.
    View in: PubMed
    Score: 0,037
  73. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. Clin Infect Dis. 2017 Jun 01; 64(11):1502-1508.
    View in: PubMed
    Score: 0,036
  74. Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014 Jun 01; 189(11):1426-34.
    View in: PubMed
    Score: 0,029
  75. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
    View in: PubMed
    Score: 0,027
  76. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012 Sep 07; 102(10):805-7.
    View in: PubMed
    Score: 0,026
  77. Performance of the PointCare NOW system for CD4 counting in HIV patients based on five independent evaluations. PLoS One. 2012; 7(8):e41166.
    View in: PubMed
    Score: 0,026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.